Launch One Acquisition Aktie - LPAA

Launch One Acquisition Corporation (LPAA) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

10,80

( - )

Gebot

10,78

Fragen

17,46

Volumen

10,82 Tagesbereich 10,82

10,39 52-Wochen-Bereich 10,85

Marktkapitalisierung

310,5M

Handelsende

10,80

Handelsbeginn

10,82

Letzte Trade

10.8

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

US$ 10.882

Ausgegebene Aktien

28.750.000

Dividendenrendite (LTM)

Kurs-Gewinn-Verhältnis

40,02

Gewinn pro Aktie (EPS)

0,27

Erlöse (LTM)

Nettogewinn (LTM)

7,72M

Launch One Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Oakland... Launch One Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Oakland, California. Mehr anzeigen

Sektor

Branche

Website

www.launchoneacquisitioncorp.com

Hauptsitz

Oakland, United States

Gegründet

2026

Launch One Acquisition Corporation is listed in the sector of the NASDAQ with ticker LPAA. The last closing price for Launch One Acquisition was US$10,80. Over the last year, Launch One Acquisition shares have traded in a share price range of US$ 10,39 to US$ 10,85.

Launch One Acquisition currently has 28.750.000 shares in issue. The market capitalisation of Launch One Acquisition is US$310,50 million. Launch One Acquisition has a price to earnings ratio (PE ratio) of 40.02.

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

HAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company...

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

HAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a...

Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition

HAIFA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company...

Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome

HAIFA, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company...

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a...

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers

HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.01	0.0926784059314	10.79	10.85	10.78	76259	10.80995864	CS
4	0.02	0.185528756957	10.78	10.85	10.74	21489	10.80867639	CS
12	0.09	0.840336134454	10.71	10.85	10.685	13526	10.77578806	CS
26	0.2375	2.24852071006	10.5625	10.85	10.53	21988	10.64961176	CS
52	0.3999	3.84515533504	10.4001	10.85	10.39	28281	10.52059211	CS
156	0.81	8.10810810811	9.99	10.85	9.96	41790	10.24074707	CS
260	0.81	8.10810810811	9.99	10.85	9.96	41790	10.24074707	CS

LPAA - Frequently Asked Questions (FAQ)

What is the current Launch One Acquisition Corporation share price?

The current share price of Launch One Acquisition Corporation is US$ 10,80

How many Launch One Acquisition Corporation shares are in issue?

Launch One Acquisition Corporation has 28.750.000 shares in issue

What is the market cap of Launch One Acquisition Corporation?

The market capitalisation of Launch One Acquisition Corporation is USD 310,5M

What is the 1 year trading range for Launch One Acquisition Corporation share price?

Launch One Acquisition Corporation has traded in the range of US$ 10,39 to US$ 10,85 during the past year

What is the PE ratio of Launch One Acquisition Corporation?

The price to earnings ratio of Launch One Acquisition Corporation is 40,02

What is the registered address of Launch One Acquisition Corporation?

The registered address for Launch One Acquisition Corporation is 180 Grand Avenue, Oakland, California, 94612

What is the Launch One Acquisition Corporation website address?

The website address for Launch One Acquisition Corporation is www.launchoneacquisitioncorp.com

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Launch One Acquisition Corporation (LPAA)

Launch One Acquisition Corporation (LPAA) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Launch One Acquisition Corporation

LPAA Neueste Nachrichten

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition

Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition

Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers

Minovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by Growth

Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome

LPAA - Frequently Asked Questions (FAQ)

LPAA Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Launch One Acquisition Corporation (LPAA)

Launch One Acquisition Corporation (LPAA) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Launch One Acquisition Corporation

LPAA Neueste Nachrichten

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition

Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition

Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers

Minovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by Growth

Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome

LPAA - Frequently Asked Questions (FAQ)

LPAA Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen